Misti Newson
Psychiatric/Mental Health · Boise, IDNPI 1295400422
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 52.1% of the total. 2025 is the largest year on record at $45,945, more than ten times the $271 reported in 2021. Among psychiatric/mental health clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $157.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$29K
- Axsome Therapeutics, Inc.$19K
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$816
- plus $3K from 11 others
What the payments were for
- Consulting fees$3,6977%
- Speaking & faculty fees$30,28754%
- Travel & lodging$11,03020%
- Food & beverage$10,39219%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 84 | $28,964 |
| Axsome Therapeutics, Inc. | 36 | $19,231 |
| Neurocrine Biosciences, Inc. | 40 | $1,254 |
| Johnson & Johnson | 19 | $1,208 |
| Otsuka America Pharmaceutical, Inc. | 33 | $1,185 |
| AbbVie | 49 | $816 |
| Alkermes, Inc. | 29 | $750 |
| Teva Pharmaceuticals USA, Inc. | 14 | $618 |
| Vanda Pharmaceuticals Inc. | 18 | $558 |
| Janssen Scientific Affairs, LLC | 4 | $249 |
| Corium, LLC | 6 | $220 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $217 |
| Supernus Pharmaceuticals, Inc. | 2 | $141 |
| Indivior Inc. | 3 | $64 |
| Lundbeck LLC | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$22,878
- Auvelity$18,606
- INVEGA SUSTENNA$945
- LYBALVI$823
- INGREZZA$596
- Fanapt$365
- ABILIFY MAINTENA$349
- ABILIFY ASIMTUFII$349
- REXULTI$346
- VRAYLAR$231
- QELBREE$125
- Austedo XR$121
- INVEGA TRINZA$118
- Azstarys$117
- UZEDY$117
- CAPLYTA$112
How this compares
$55,594 in reported general payments places this provider in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 38 | $432,947 |
| Invega SustennaPaliperidone Palmitate | 56 | $195,741 |
| VraylarCariprazine Hcl | 62 | $87,950 |
| AustedoDeutetrabenazine | 18 | $76,791 |
| RexultiBrexpiprazole | 40 | $73,263 |
| Abilify AsimtufiiAripiprazole | 11 | $63,055 |
| AuvelityDextromethorphan Hbr/Bupropion | 63 | $61,800 |
| AristadaAripiprazole Lauroxil | 12 | $42,652 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $25,017 |
| TrintellixVortioxetine Hydrobromide | 23 | $17,260 |
| Lamotrigine ErLamotrigine | 44 | $11,373 |
| Aripiprazole | 115 | $7,677 |
| AdderallDextroamphetamine/Amphetamine | 11 | $7,501 |
| Atomoxetine Hcl | 44 | $6,881 |
| Paliperidone ErPaliperidone | 39 | $6,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $618 | $509,73856 claims |
| Johnson & JohnsonInvega Sustenna | $1,208 | $195,74156 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii | $1,185 | $136,31851 claims |
| AbbVieVraylar | $816 | $87,95062 claims |
| Alkermes, Inc.Aristada, Lybalvi | $750 | $67,66927 claims |
| Axsome Therapeutics, Inc.Auvelity | $19,231 | $61,80063 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $45 | $24,76134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Boise
- Carey CrillBoise$19K
- Julie SchraderBoise$9K
- Susan DayBoise$9K
- Grace MensahBoise$6K
- Katie HarpBoise$6K
- Eliza SalazarBoise$5K
- Brigitta PantherBoise$5K
- Dawn LoceyBoise$3K
- Lisa BrynerBoise$3K
- Jenny PinsonBoise$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.